# US 9,518,033 B2 · (4E)-4-(4-substituted benzylideneamino)-2,3-dihydro-3-substituted-2-thioxothiazole-5-carbonitriles as A2AR antagonist and process for preparation thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,518,033 B2
- Document ID: US9518033B2
- Status: Granted
- Kind: B2
- Application number: 14/758,994
- Filed: 2014-01-03
- Published: 2015-11-26
- Granted: 2016-12-13
- Earliest claimed: 2013-01-03
- Assignees: Council of Scientific and Industrial Research
- Applicants: Council of Scientific & Industrial Research
- Inventors: Pratibha Mehta Luthra; Chandrabhushan Mishra
- Web page: https://patentgrep.com/patent/US9518033B2

## CPC

- C07D 277/54: Nitrogen and either oxygen or sulfur atoms
- A61P 25/00: Drugs for disorders of the nervous system
- C07D 277/56: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides (4E)-4-(4-substituted benzylideneamino)-2,3-dihydro-3-substituted-2-thioxothiazole-5-carbonitriles of general formula A, below, and a process for the preparation thereof. The compounds of present invention are useful in the treatment of central nervous disorders including, Parkinson disease, Huntington's disease, attention disorder, cognition, Alzheimer disease, depression and hypertension.

## Claims

### Claim 1

A compound of formula A and pharmaceutically acceptable salts thereof,
wherein R is selected from the group consisting of hydrogen, alkyl having carbon numbers up to 10, cycloalkyl, aromatic, aromatics having substituents selected from the group consisting of halogen, OH, COOH, OCH3, and alkyl, and substituted heterocyclics including heteroaromatics compounds having up to seven members; R1 is selected from nucleophiles selected from the group consisting of halides, O along with a substituent selected from the group consisting of hydrogen, alkyl having carbon numbers up to 10, cycloalkyl, aromatic, aromatics having substituents selected from the group consisting of halogen, OH, COOH, OCH3, and alkyl, and substituted heterocyclics including heteroaromatics compounds having up to seven members, S along with a substituent selected from the group consisting of hydrogen, alkyl having carbon numbers up to 10, cycloalkyl, aromatic, aromatics having substituents selected from the group consisting of halogen, OH, COOH, OCH3, and alkyl, and substituted heterocyclics including heteroaromatics compounds having up to seven members, COO along with a substituent selected from the group consisting of hydrogen, alkyl having carbon numbers up to 10, cycloalkyl, aromatic, aromatics having substituents selected from the group consisting of halogen, OH, COOH, OCH3, and alkyl, and substituted heterocyclics including heteroaromatics compounds having up to seven members, NR2R3 wherein R2 and R3 are selected from the group consisting of hydrogen, alkyl having carbon numbers up to 10, cycloalkyl, aromatic, aromatics having substituents selected from the group consisting of halogen, OH, COOH, OCH3, and alkyl, substituted heterocyclics including heteroaromatics compounds having up to seven members and substituted amino, and alkyl having up to five carbon chain.

### Claim 2

A pharmaceutical compound selected from the group consisting of:
a. 4E)-4-(4-fluorobenzylideneamino)-3-ethyl-2,3-dihydro-2-thioxothiazole-5-carbonitrile,
b. (4E)4-(4-fluorobenzylideneamino)-3-propyl-2,3-dihydro-2-thioxothiazole-5-carbonitrile,
c. (4E)-4-fluorobenzylideneamino)-3-butyl-2,3-dihydro-2-thioxothiazole-5-carbonitrile,
d. (4E)-4-(4-fluorobenzylideneamino)-3-phenylethyl-2,3-dihydro-2-thioxothiazole-5-carbonitrile,
e. (4E)-4-(4-fluorobenzylideneamino)-3-phenyl-2,3-dihydro-2-thioxothiazole-5-carbonitrile,
f (4E)-4-(4-chlorobenzylideneamino)-3-ethyl-2,3-dihydro-2-thioxothiazole-5-carbonitrile,
g. (4E)4-(4-chlorobenzylideneamino)-3-propyl-2,3-dihydro-2-thioxothiazole-5-carbonitrile,
h. (4E)-4-(chlorobenzylideneamino)-3-butyl-2,3-dihydro-2-thioxothiazole-5-carbonitrile,
i. (4E)4-(4-chlorobenzylideneamino)-3-phenyl-2,3-dihydro-2-thioxothiazole-5-carbonitrile
j. (4E)-4-(4-Bromobenzylideneamino)-3-ethyl-2,3-dihydro-2-thioxothiazole-5-carbonitrile,
k. (4E)4-(4-bromobenzylideneamino)-3-propyl-2,3-dihydro-2-thioxothiazole-5-carbonitrile,
l. (4E)-4-(4-bromobenzylideneamino)-3-butyl-2,3-dihydro-2-thioxothiazole-5-carbonitrile,
m. (4E)4-(4-bromobenzylideneamino)-3-phenylethyl-2,3-dihydro-2-thioxothiazole-5-carbonitrile, and
n. (4E)4-(4-bromobenzylideneamino)-3-phenyl-2,3-dihydro-2-thioxothiazole-5-carbonitrile.

### Claim 3 (depends on 2)

The pharmaceutical compound of claim 2, wherein the compound exhibits adenosine A2A receptor affinity (KiA2A) in the range of 0.004 to 10.98 nm.

### Claim 4 (depends on 2)

The pharmaceutical compound of claim 2, wherein the compound is:
n. (4E)4-(4-bromobenzylideneamino)-3-phenyl-2,3-dihydro-2-thioxothiazole-5-carbonitrile and exhibits Adenosine A2A receptor antagonistic ability 0.56 pmol/ml cAMP concentration.

### Claim 5 (depends on 2)

The pharmaceutical compound of claim 2, wherein the compound exhibits the significant attenuation of catalepsy score in haloperidol-induced mice at the dose of 10 mg/kg (0.75±0.144).

### Claim 6 (depends on 1)

A process for preparation of the compound of claim 1, wherein said process comprises the step of
reacting a compound of formula 1,
with p-substituted benzaldehyde of the formula,
wherein R is selected from a group consisting of ethyl, propyl, butyl, and phenyl and the reaction is carried out in polar solvents selected from the group consisting of chloroform, dichloromethane, ethanol and acetic acid in the presence of Lewis acid catalyst selected from the group consisting of AlCl3 BF3, ZnCl2, and FeCl3 (2-3 mole %) at a temperature ranging between 20 to 30° C. for a period ranging between 6-12 hr.

### Claim 7 (depends on 6)

The process as claimed in claim 6, wherein p-substituted benzaldehyde is selected from a group consisting of fluorobenzaldehyde, chlorobenzaldehyde and bromo benzaldehyde.